Altre lingue Active Biotech AB

Azioni

ACTI

SE0001137985

Biotecnologia

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 18:00:00 05/12/2025			Variaz. 5gg	Var. 1 gen.
0,0640 ^SEK	-1,54%		+9,59%	-41,18%

25/11	Active Biotech otterrà il brevetto statunitense per la formulazione farmaceutica con Tasquinimod	MT
25/11	Active Biotech: Brevetto Sarà Concesso negli Stati Uniti	RE

Altre lingue

Active Biotech to Receive US Patent for Pharmaceutical Formulation with Tasquinimod	25/11
Active Biotech: Patent to be granted in U.S.	25/11
Active Biotech : patent related to a pharmaceutical formulation of tasquinimod will be granted in the US	25/11
Active Biotech’s patent related to a pharmaceutical formulation of tasquinimod will be granted in the US	25/11
Active Biotech AB Announces Patent Related to A Pharmaceutical Formulation of Tasquinimod Will Be Granted in the US	25/11
Active Biotech : The subscription period in Active Biotech's rights issue begins today	25/11
The subscription period in Active Biotech’s rights issue begins today	25/11
Positive preclinical tasquinimod data in myelofibrosis published in Blood Advances	24/11
Active Biotech Announces Preclinical Data with Tasquinimod in Myelofibrosis	24/11
Active Biotech publishes information document regarding rights issue	20/11
Extraordinary General Meeting of Active Biotech AB	19/11
Active Biotech (Q3 Review) - Rights Issue Funds 2026-2027	10/11
Active Biotech Q3 operating loss of SEK 6.0 million	06/11
Active Biotech Interim Report Q3 2025	06/11
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	06/11
Preclinical data of tasquinimod in combination with T cell activation to be presented at ASH 2025	03/11
The LION Study: Safety, Tolerability and Distribution of Topical Laquinimod Eye Drops, an Innovative Immunomodulator Targeting Aryl Hydrocarbon Receptor	22/10
Active Biotech announces rights issue of about SEK 70 mln	20/10
NOTICE OF EXTRAORDINARY GENERAL MEETING	17/10
Active Biotech announces a fully secured rights issue of approximately SEK 70 million	17/10
Active Biotech to present positive Lion studies results in Orlando	10/09
Active Biotech : Positive results from Active Biotech's clinical phase I LION study to be presented at AAO 2025 in October	10/09
Positive results from Active Biotech’s clinical phase I LION study to be presented at AAO 2025 in October	10/09
Active Biotech Announces Positive Results from the LION Study	10/09
Active Biotech Q2 2025 - On the Eve of a Laquinimod Deal	25/08

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Active Biotech AB

Azioni

ACTI

SE0001137985

Biotecnologia

Altre lingue

Filtri